Clinical Trial Update: Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial update for Anti-Tac(Fv)-PE38 (LMB-2) in cutaneous T-cell lymphomas has been completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Anti-Tac(Fv)-PE38 (LMB-2) (Anti-Tac(Fv)-PE38)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, T-Cell | Phase 2 | Status: COMPLETED | Results posted: 2012-10-24